Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Phase Formation and Oxidation Behavior at 500 °C in a Ni-Co-Al Thin-Film Materials Library.

Naujoks D, Richert J, Decker P, Weiser M, Virtanen S, Ludwig A.

ACS Comb Sci. 2016 Sep 12;18(9):575-82. doi: 10.1021/acscombsci.6b00052. Epub 2016 Jul 20.

PMID:
27392254
2.

Forensic engineering of advanced polymeric materials. Part III - Biodegradation of thermoformed rigid PLA packaging under industrial composting conditions.

Musioł M, Sikorska W, Adamus G, Janeczek H, Richert J, Malinowski R, Jiang G, Kowalczuk M.

Waste Manag. 2016 Jun;52:69-76. doi: 10.1016/j.wasman.2016.04.016. Epub 2016 Apr 18.

PMID:
27103398
3.

Testing macular letter recognition - reliability and influence of refraction errors.

Eisenbarth W, Richert J, MacKeben M.

Clin Exp Optom. 2016 Jul;99(4):322-7. doi: 10.1111/cxo.12360. Epub 2016 Apr 17.

4.

Evaluating more naturalistic outcome measures: A 1-year smartphone study in multiple sclerosis.

Bove R, White CC, Giovannoni G, Glanz B, Golubchikov V, Hujol J, Jennings C, Langdon D, Lee M, Legedza A, Paskavitz J, Prasad S, Richert J, Robbins A, Roberts S, Weiner H, Ramachandran R, Botfield M, De Jager PL.

Neurol Neuroimmunol Neuroinflamm. 2015 Oct 15;2(6):e162. doi: 10.1212/NXI.0000000000000162. eCollection 2015 Dec.

5.

The diagnostic challenges of separating chronic ulcerative stomatitis from oral lichen planus.

Qari H, Villasante C, Richert J, Rees T, Kessler H.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Nov;120(5):622-7. doi: 10.1016/j.oooo.2015.07.018. Epub 2015 Jul 22.

PMID:
26337216
6.

Physical activity among adults with obesity: testing the Health Action Process Approach.

Parschau L, Barz M, Richert J, Knoll N, Lippke S, Schwarzer R.

Rehabil Psychol. 2014 Feb;59(1):42-9. doi: 10.1037/a0035290. Epub 2014 Jan 20.

PMID:
24446673
7.

Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis.

Teunissen C, Menge T, Altintas A, Álvarez-Cermeño JC, Bertolotto A, Berven FS, Brundin L, Comabella M, Degn M, Deisenhammer F, Fazekas F, Franciotta D, Frederiksen JL, Galimberti D, Gnanapavan S, Hegen H, Hemmer B, Hintzen R, Hughes S, Iacobaeus E, Kroksveen AC, Kuhle J, Richert J, Tumani H, Villar LM, Drulovic J, Dujmovic I, Khalil M, Bartos A.

Mult Scler. 2013 Nov;19(13):1802-9. doi: 10.1177/1352458513488232. Epub 2013 May 21.

PMID:
23695446
8.

Self-regulation prompts can increase fruit consumption: a one-hour randomised controlled online trial.

Lange D, Richert J, Koring M, Knoll N, Schwarzer R, Lippke S.

Psychol Health. 2013;28(5):533-45. doi: 10.1080/08870446.2012.751107. Epub 2013 Jan 2.

PMID:
23282217
9.

Stages of health behavior change and mindsets: a latent class approach.

Richert J, Schüz N, Schüz B.

Health Psychol. 2013 Mar;32(3):273-82. doi: 10.1037/a0028915. Epub 2012 Jun 18.

PMID:
22708517
10.

Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS.

Bushnell SE, Zhao Z, Stebbins CC, Cadavid D, Buko AM, Whalley ET, Davis JA, Versage EM, Richert JR, Axtell RC, Steinman L, Medori R.

Neurology. 2012 Aug 7;79(6):531-7. doi: 10.1212/WNL.0b013e318259e123. Epub 2012 May 9.

11.

[Japanese students and assistants of the medical faculty of Strasbourg from 1872 to 1918].

Le Minor JM, Richert JB.

Hist Sci Med. 2011 Oct-Dec;45(4):403-14. French.

PMID:
22400479
12.

Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with Natalizumab.

Wang YC, Sandrock A, Richert JR, Meyerson L, Miao X.

Neurol Res Int. 2011;2011:195831. doi: 10.1155/2011/195831. Epub 2011 Dec 26.

13.

Synergistic effects of planning and self-efficacy on physical activity.

Koring M, Richert J, Lippke S, Parschau L, Reuter T, Schwarzer R.

Health Educ Behav. 2012 Apr;39(2):152-8. doi: 10.1177/1090198111417621. Epub 2011 Dec 13.

PMID:
22167316
14.

A combined planning and self-efficacy intervention to promote physical activity: a multiple mediation analysis.

Koring M, Richert J, Parschau L, Ernsting A, Lippke S, Schwarzer R.

Psychol Health Med. 2012;17(4):488-98. doi: 10.1080/13548506.2011.608809. Epub 2011 Oct 18.

PMID:
22007933
15.

Changes in social-cognitive variables are associated with stage transitions in physical activity.

Parschau L, Richert J, Koring M, Ernsting A, Lippke S, Schwarzer R.

Health Educ Res. 2012 Feb;27(1):129-40. doi: 10.1093/her/cyr085. Epub 2011 Sep 2.

PMID:
21890843
16.

Intervention-engagement and its role in the effectiveness of stage-matched interventions promoting physical exercise.

Richert J, Lippke S, Ziegelmann JP.

Res Sports Med. 2011 Jul-Sep;19(3):145-61. doi: 10.1080/15438627.2011.583164.

PMID:
21722003
17.

Translating intentions into nutrition behaviors via planning requires self-efficacy: evidence from Thailand and Germany.

Schwarzer R, Richert J, Kreausukon P, Remme L, Wiedemann AU, Reuter T.

Int J Psychol. 2010 Aug 1;45(4):260-8. doi: 10.1080/00207591003674479.

PMID:
22044011
18.

Differential effects of planning and self-efficacy on fruit and vegetable consumption.

Richert J, Reuter T, Wiedemann AU, Lippke S, Ziegelmann J, Schwarzer R.

Appetite. 2010 Jun;54(3):611-4. doi: 10.1016/j.appet.2010.03.006. Epub 2010 Mar 20.

PMID:
20227450
19.

Proof of concept studies for tissue-protective agents in multiple sclerosis.

Mehta LR, Schwid SR, Arnold DL, Cutter GR, Aradhye S, Balcer LJ, Calabresi PA, Cohen JA, Cole PE, Glanzman R, Goelz S, Inglese M, Kapoor R, Kappos L, Kreitman R, Lublin FD, Mann A, Marrie RA, O'Looney P, Polman CH, Ravina BM, Reingold SC, Richert JR, Sandrock AW, Waubant E.

Mult Scler. 2009 May;15(5):542-6. doi: 10.1177/1352458508101939. Review.

PMID:
19389749
20.

Differential diagnosis of suspected multiple sclerosis: a consensus approach.

Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galetta SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban X, Panitch H, Richert JR, Reingold SC, Polman CH.

Mult Scler. 2008 Nov;14(9):1157-74. doi: 10.1177/1352458508096878. Epub 2008 Sep 19.

21.

Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment.

Polman CH, Reingold SC, Barkhof F, Calabresi PA, Clanet M, Cohen JA, Cutter GR, Freedman MS, Kappos L, Lublin FD, McFarland HF, Metz LM, Miller AE, Montalban X, O'Connor PW, Panitch H, Richert JR, Petkau J, Schwid SR, Sormani MP, Thompson AJ, Weinshenker BG, Wolinsky JS.

Neurology. 2008 Mar 25;70(13 Pt 2):1134-40. doi: 10.1212/01.wnl.0000306410.84794.4d.

PMID:
18362273
22.

Improvement of field matching in segmented-field electron conformal therapy using a variable-SCD applicator.

Richert JD, Hogstrom KR, Fields RS, Matthews KL 2nd, Boyd RA.

Phys Med Biol. 2007 May 7;52(9):2459-81. Epub 2007 Apr 10.

PMID:
17440246
23.

Proteome analysis of myocardial tissue following ischemia and reperfusion--effects of complement inhibition.

Buerke M, Schwertz H, Längin T, Buerke U, Prondzinsky R, Platsch H, Richert J, Bomm S, Schmidt M, Hillen H, Lindemann S, Blaschke G, Müller-Werdan U, Werdan K.

Biochim Biophys Acta. 2006 Oct;1764(10):1536-45. Epub 2006 May 15.

PMID:
17045855
24.

Intramural delivery of Sirolimus prevents vascular remodeling following balloon injury.

Buerke M, Guckenbiehl M, Schwertz H, Buerke U, Hilker M, Platsch H, Richert J, Bomm S, Zimmerman GA, Lindemann S, Mueller-Werdan U, Werdan K, Darius H, Weyrich AS.

Biochim Biophys Acta. 2007 Jan;1774(1):5-15. Epub 2006 May 19.

25.

Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis.

Frohman EM, Havrdova E, Lublin F, Barkhof F, Achiron A, Sharief MK, Stuve O, Racke MK, Steinman L, Weiner H, Olek M, Zivadinov R, Corboy J, Raine C, Cutter G, Richert J, Filippi M.

Arch Neurol. 2006 Apr;63(4):614-9. No abstract available.

PMID:
16606781
26.

A phase I study of the safety of honeybee venom extract as a possible treatment for patients with progressive forms of multiple sclerosis.

Castro HJ, Mendez-Lnocencio JI, Omidvar B, Omidvar J, Santilli J, Nielsen HS Jr, Pavot AP, Richert JR, Bellanti JA.

Allergy Asthma Proc. 2005 Nov-Dec;26(6):470-6.

PMID:
16541972
27.

Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.

Herndon RM, Rudick RA, Munschauer FE 3rd, Mass MK, Salazar AM, Coats ME, Labutta R, Richert JR, Cohan SL, Genain C, Goodkin D, Toal M, Riester K.

Mult Scler. 2005 Aug;11(4):409-19.

PMID:
16042223
29.

Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis.

Stuart WH, Cohan S, Richert JR, Achiron A.

Neurology. 2004 Dec 14;63(11 Suppl 5):S19-27. Review.

PMID:
15596732
30.

Human transcription factor Sp3: genomic structure, identification of a processed pseudogene, and transcript analysis.

Moran KM, Crusio RH, Chan CH, Grekova MC, Richert JR.

Gene. 2004 Oct 27;341:235-47.

PMID:
15474306
31.

Structure-based discovery of nonpeptidic small organic compounds to block the T cell response to myelin basic protein.

Koehler NK, Yang CY, Varady J, Lu Y, Wu XW, Liu M, Yin D, Bartels M, Xu BY, Roller PP, Long YQ, Li P, Kattah M, Cohn ML, Moran K, Tilley E, Richert JR, Wang S.

J Med Chem. 2004 Oct 7;47(21):4989-97.

PMID:
15456243
32.

Role of an internal ribosome entry site in the translational control of the human transcription factor Sp3.

Hernandez EM, Chan CH, Xu B, Notario V, Richert JR.

Int J Oncol. 2004 Mar;24(3):719-24.

PMID:
14767558
33.

Transient backbending behavior in the Ising model with fixed magnetization.

Gulminelli F, Carmona JM, Chomaz P, Richert J, Jiménez S, Regnard V.

Phys Rev E Stat Nonlin Soft Matter Phys. 2003 Aug;68(2 Pt 2):026119. Epub 2003 Aug 20.

PMID:
14525061
34.

Dynamics of many-particle fragmentation in a cellular automaton model.

Lejeune A, Perdang J, Richert J.

Phys Rev E Stat Nonlin Soft Matter Phys. 2003 Apr;67(4 Pt 2):046214. Epub 2003 Apr 24.

PMID:
12786467
35.

AUA as a translation initiation site in vitro for the human transcription factor Sp3.

Hernandez EM, Johnson A, Notario V, Chen A, Richert JR.

J Biochem Mol Biol. 2002 May 31;35(3):273-82.

PMID:
12297010
36.

Sp3 expression in immune cells: a quantitative study.

Grekova MC, Salerno K, Mikkilineni R, Richert JR.

Lab Invest. 2002 Sep;82(9):1131-8.

PMID:
12218073
37.

Two-dimensional analysis of myocardial protein expression following myocardial ischemia and reperfusion in rabbits.

Schwertz H, Längin T, Platsch H, Richert J, Bomm S, Schmidt M, Hillen H, Blaschke G, Meyer J, Darius H, Buerke M.

Proteomics. 2002 Aug;2(8):988-95.

PMID:
12203894
38.

Application of cellular automata to N-body systems.

Lejeune A, Perdang J, Richert J.

Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics. 1999 Sep;60(3):2601-11.

PMID:
11970061
39.

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. 1997.

Rudick RA, Goodkin DE, Jacobs LD, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Fischer JS, Granger CV, Simon JH, Alam JJ, Simonian NA, Campion MK, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Weistock-Guttman B, Whitham RH; Multiple Sclerosis Collaborative Research Group.

Neurology. 2001 Dec;57(12 Suppl 5):S25-30. No abstract available.

PMID:
11902591
40.

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN.

Arthritis Rheum. 2001 Dec;44(12):2862-9.

41.

Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group.

Fischer JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Goodkin DE, Granger CV, Simon JH, Grafman JH, Lezak MD, O'Reilly Hovey KM, Perkins KK, Barilla-Clark D, Schacter M, Shucard DW, Davidson AL, Wende KE, Bourdette DN, Kooijmans-Coutinho MF.

Ann Neurol. 2000 Dec;48(6):885-92.

PMID:
11117545
42.

A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group.

Simon JH, Lull J, Jacobs LD, Rudick RA, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Sheeder J, Miller D, McCabe K, Serra A, Campion MK, Fischer JS, Goodkin DE, Simonian N, Lajaunie M, Wende K, Martens-Davidson A, Kinkel RP, Munschauer FE 3rd.

Neurology. 2000 Jul 25;55(2):185-92.

PMID:
10908888
43.

EAE susceptibility in FVB mice.

Baker AM, Grekova MC, Richert JR.

J Neurosci Res. 2000 Jul 15;61(2):140-5.

PMID:
10878586
44.
45.

A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

Simon JH, Jacobs LD, Campion MK, Rudick RA, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Simonian N, Lajaunie M, Miller DE, Wende K, Martens-Davidson A, Kinkel RP, Munschauer FE 3rd, Brownscheidle CM.

Neurology. 1999 Jul 13;53(1):139-48.

PMID:
10408550
46.

Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

Rudick RA, Cookfair DL, Simonian NA, Ransohoff RM, Richert JR, Jacobs LD, Herndon RM, Salazar AM, Fischer JS, Granger CV, Goodkin DE, Simon JH, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munchsauer FE, O'Reilly K, Priore RL, Whitham RH, et al.

J Neuroimmunol. 1999 Jan 1;93(1-2):8-14.

PMID:
10378864
47.

Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. The Multiple Sclerosis Collaborative Research Group (MSCRG).

Goodkin DE, Priore RL, Wende KE, Campion M, Bourdette DN, Herndon RM, Fischer JS, Jacobs LD, Cookfair DL, Rudick RA, Richert JR, Salazar AM, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Whitham RH, et al.

Mult Scler. 1998 Dec;4(6):480-6.

PMID:
9987756
48.

Human Herpesvirus-6 (HHV-6) infection in multiple sclerosis: a preliminary report.

Ablashi DV, Lapps W, Kaplan M, Whitman JE, Richert JR, Pearson GR.

Mult Scler. 1998 Dec;4(6):490-6.

PMID:
9987758
49.

Differential recognition of MBP epitopes in BALB/c mice determines the site of inflammatory disease induction.

Yoshizawa I, Bronson R, Ben-Nun A, Richert JR, Dorf ME, Abromson-Leeman S.

J Neuroimmunol. 1998 Aug 14;89(1-2):73-82.

PMID:
9726828
50.

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W, Coats ME, Goodkin DE, Weinstock-Guttman B, Herndon RM, Mass MK, Richert JR, Salazar AM, Munschauer FE 3rd, Cookfair DL, Simon JH, Jacobs LD.

Neurology. 1998 May;50(5):1266-72.

PMID:
9595973

Supplemental Content

Loading ...
Support Center